Replies to post #24879 on Mymetics Corp (MYMX)

[Work Harder]

MPER from gp41 is a promising antigen segment of the viral envelope recognized by a number of broadly neutralizing antibodies and represents a promising vaccine target. Projects funded through this program focus on the development of lipid nanoparticles containing mRNAs for the induction of protective non-neutralizing or neutralizing antibodies. This includes developing the cGMP manufacturing processes for mRNA immunogens as well as the nanoparticle formulations for Phase 1 trials. Additional work involving influenza virosomes that display surface-elongated HIV gp41 peptides was funded to manufacture new virosome

VTRB is also managing the Regulatory and Investigational New Drug (IND) submission to FDA for membrane proximal external region (MPER) peptide-liposome nanoparticles for use in a first-in-man Phase I clinical trial to evaluate safety and immunogenicity. MPER from gp41 is a promising antigen segment of the viral envelope recognized by a number of broadly neutralizing antibodies and represents a promising vaccine target. Projects funded through this program focus on the development of lipid nanoparticles containing mRNAs for the induction of protective non-neutralizing or neutralizing antibodies. This includes developing the cGMP manufacturing processes for mRNA immunogens as well as the nanoparticle formulations for Phase 1 trials. Additional work involving influenza virosomes that display surface-elongated HIV gp41 peptides was funded to manufacture new virosome vaccine candidates in a form that can be delivered through a nasal spray.